EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Real-World Effectiveness of Guselkumab for Induction of Remission in Crohn’s Disease: A Prospective Multicentre Cohort Study with Propensity Score-Matched Comparison to Risankizumab

Maitha Al Hosani, Noorah Al Hosani, Mohamed Nasir Alzaabi, Maryam A Alahmad, Nadeen Mamon Omar, Camille Conde Oribiana, Enas Fouad Ahmed, Ishtiaq Ahmed, Kishore Kumar Chitra Kumar, Sofia Hanif, Khalid Izzeldin Elfatih Barakat, Khalid Osman Elamin Elsayed und 1 weitere

Crohn's & Colitis 360 · 19.06.2026

DOI: 10.1093/crocol/otag061 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Crohn's & Colitis 360, online erschienen am 19.06.2026. Verfasst von Maitha Al Hosani und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

No head-to-head trials compare selective interleukin-23 inhibitors in Crohn’s disease (CD), leaving clinicians without direct evidence to guide treatment selection. We aimed to evaluate real-world induction effectiveness of guselkumab in CD and perform propensity score-matched (PSM) comparisons against risankizumab.

Methods

This prospective multicentre study included adults with moderate-to-severe CD initiating guselkumab in the United Arab Emirates. The primary outcome was clinical remission at Week 12 (Harvey-Bradshaw Index <5). Full propensity score matching between guselkumab and risankizumab cohorts controlled for 12 covariates including disease phenotype, baseline endoscopic and biochemical activity, surgical history, and current smoking status.

Results

Fifty-one guselkumab and 60 risankizumab patients were included. In the guselkumab cohort, 71% were advanced therapy-exposed with a median of 2 prior advanced therapies. At Week 12, clinical remission was achieved in 51% (26/51) and clinical response in 86% (44/51). Median CRP decreased from 8.5 to 3.0 mg/L (p = 0.002) and faecal calprotectin from 216 to 80 ug/g (p < 0.001). Effectiveness was consistent regardless of prior treatment history. On univariable analysis, higher baseline HBI (OR 0.77, p = 0.011), SES-CD (OR 0.87, p = 0.049), and CRP (OR 0.94, p = 0.019) were associated with lower remission likelihood. Maintenance dosing was 100 mg Q8W in 73% and 200 mg Q4W in 27%. PSM analysis demonstrated comparable clinical remission (51% vs 50%, p > 0.9) and clinical response (86% vs 87%, p = 0.87) between guselkumab and risankizumab, with no significant between-group biomarker differences.

Conclusions

Guselkumab demonstrated robust real-world induction effectiveness comparable to risankizumab across clinical and biochemical outcomes. These findings warrant confirmation in larger, longer-term comparative studies with endoscopic endpoints.

Schlagwörter

Stichwörter der Autor:innen

Crohn’s diseaseIL-23 inhibitorscomparative effectivenessguselkumabinflammatory bowel diseasepropensity score matchingreal-world evidencerisankizumab

Autor:innen und Institutionen

  • Department of Gastroenterology, Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates.
  • Burjeel Institute of Digestive Health, Burjeel Hospital, Abu Dhabi, United Arab Emirates.
  • Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom.
  • College of Medicine and Health Sciences, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates.

ORCID-Profile: Mohammed Nabil Quraishi

Zitieren

APA

Al Hosani, M., Al Hosani, N., Alzaabi, M. N., Alahmad, M. A., Omar, N. M., Oribiana, C. C., Ahmed, E. F., Ahmed, I., Chitra Kumar, K. K., Hanif, S., Barakat, K. I. E., Elsayed, K. O. E., & Quraishi, M. N. (2026). Real-World Effectiveness of Guselkumab for Induction of Remission in Crohn’s Disease: A Prospective Multicentre Cohort Study with Propensity Score-Matched Comparison to Risankizumab. Crohn's & Colitis 360. https://doi.org/10.1093/crocol/otag061

Vancouver

Al Hosani M, Al Hosani N, Alzaabi MN, Alahmad MA, Omar NM, Oribiana CC, et al. Real-World Effectiveness of Guselkumab for Induction of Remission in Crohn’s Disease: A Prospective Multicentre Cohort Study with Propensity Score-Matched Comparison to Risankizumab. Crohn's & Colitis 360. 2026. doi:10.1093/crocol/otag061

BibTeX
@article{AlHosani2026,
  author = {Al Hosani, Maitha and Al Hosani, Noorah and Alzaabi, Mohamed Nasir and Alahmad, Maryam A and Omar, Nadeen Mamon and Oribiana, Camille Conde and Ahmed, Enas Fouad and Ahmed, Ishtiaq and Chitra Kumar, Kishore Kumar and Hanif, Sofia and Barakat, Khalid Izzeldin Elfatih and Elsayed, Khalid Osman Elamin and Quraishi, Mohammed Nabil},
  title = {Real-World Effectiveness of Guselkumab for Induction of Remission in Crohn’s Disease: A Prospective Multicentre Cohort Study with Propensity Score-Matched Comparison to Risankizumab},
  journal = {Crohn's & Colitis 360},
  year = {2026},
  doi = {10.1093/crocol/otag061}
}
Kostenlos starten →